How much evidence do we need before our public health officials realize that we are dealing with an antibiotic resistant/tolerant superbug? Almost four decades of denial.
--------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov
Cc: (99 Undisclosed recipients)
Date: April 5, 2020 at 10:18 AM
Subject: Microbiologist Tom Grier’s Letter to the Editor of Pharmaceutical-Technology
To the Tick-Borne Disease Working Group,
I would like to share the following letter to the editor sent by microbiologist Tom Grier in reference to the following pharmaceutical-technology.com article:
Lyme disease: What’s actually going on here?
https://www.pharmaceutical-technology.com/features/lyme-disease-whats-actually-going-on-here/
Published 2 APRIL 2020
By Chloe Kent Chloe.Kent@globaldata.com
Tom Grier’s Letter to the Editor:
---------- Original Message ----------
From: Tom Grier <tomgrier@gmail.com>
To: editorialenquiries@globaldata.com, Tom Grier <donatebrain@gmail.com>
Date: April 3, 2020 at 5:15 PM
Subject: Attention Chloe Kent
A few comments about the article:
2 APRIL 2020
Lyme disease: What’s actually going on here?
By Chloe Kent
I am a microbiologist that has done 25+ years of work on Borreliosis and the effects of Borrelia infection of the human brain.
The only reason there is a controversy about the persistence of LIVE Borrelia spirochetes in patients that have been treated with antibiotics is simply that the CDC, NIH, Yale, Mayo Clinic, and SUNY all have patents on blood-tests for Lyme disease, and base their conclusions on blood tests. This is not only a financial conflict of interest, but now is a problem with repuitations and jobs.
The most notable Lyme disease experts have not done a single brain autopsy to confirm the absence of infection. Not one tax-payer dollar has been spent on brain pathology to investigate Borrelia species in dementia, MS, or chronic Lyme disease or neuro Borrelia myamotoi.
Several private funded pathologists have done the research and found persistence and some interesting pathology.
Borrelia can persist behind the blood-brain-barrier for decades. Further, the spirochete can take reefuge inside human brain-neurons. No blood test can detect this type of persistence, because the peripheral immune system stops detecting the infection.
To make things more difficult both Borrelia burgdorferi and Borrelia myamotoi form clusters surrounded by secreted glycoprotein gel and embeds inside amyloid plaques.
This is low hanging fruit waiting to be picked by the CDC or State Health Departments, but they refuse to do the brain pathology needed, even though many brain-banks offer ample easy access and samples they haven't and won't spend a dime that would ruin the reputations of the serology-cartel.
Attached are just a few of hundreds of images showing persistence despite negative blood tests.
(Shared in Carl Tuttle’s Dropbox storage area)
1. B. myamotoi in Alzheimer's plaque.jpeg
https://www.dropbox.com/s/eoxjphrjdpn04vm/B.%20myamotoi%20in%20Alzheimer%27s%20plaque.jpeg?dl=0
2. Borrelia Pathology Poster br.pdf
https://www.dropbox.com/s/29q74d74xszyhoa/Borrelia%20Pathology%20Poster%20br.pdf?dl=0
3. Forris Intra Bb.jpeg
https://www.dropbox.com/s/79ecck1tki1daek/Forris%20Intra%20Bb.jpeg?dl=0
4. InternalBb Neuron Mac.jpeg
https://www.dropbox.com/s/p6u53xih3uoj4m3/InternalBb%20Neuron%20Mac.jpeg?dl=0
5. livengoode neuron.jpeg
https://www.dropbox.com/s/q6za8fxacoadlel/livengoode%20neuron.jpeg?dl=0
6. Screen Shot 2019-07-03 at 8.45.05 PM.png
https://www.dropbox.com/s/x31bfpihkb58ifv/Screen%20Shot%202019-07-03%20at%208.45.05%20PM.png?dl=0
7. Screen Shot 2019-07-03 at 8.45.16 PM.png
https://www.dropbox.com/s/7ff9pyvz7gaaxjt/Screen%20Shot%202019-07-03%20at%208.45.16%20PM.png?dl=0
-End of letter to the editor-_____________________________________________________
About Tom Grier:
HS 85 – Bad Science and Lyme Disease with Tom Grier
https://www.holisticsurvival.com/podcast/hs-85-bad-science-and-lyme-disease-with-tom-grier/
Excerpt:
“Thomas Grier M.S. studied Clinical Immunology and Microbiology at the University of MN Duluth, and began a doctorate program in Geriatrics until the program was discontinued. He then worked on human vaccine development and developed antibody testing to detect bacteria in Pylonephritis. He also worked on a T-cell model of Leukemia in mice trying to target the immune system against Leukemia-Lymphocytic markers to reduce Lymphocyte levels. In 1990, he was misdiagnosed with MS and was finally diagnosed with Lyme Encephalitis in 1991. Following his fight with recovering from this disease, he wrote the “Lyme Disease Survival Manual” for patients, which sold worldwide. Currently, Tom is the Executive Director of Pathology Studies at MIBDEC. MIBDEC is an non-profit organization trying to register Dementia and MS patients to donate their brains to science to look for spirochetes (Lyme) as a possible connection to some (not all) dementias. He does this because of the refusal by health departments, the NIH or CDC to do the proper work to rule out spirochetes within the brain as a cause of our increased rate of dementia in America and around the temperate latitudes of the Northern Hemisphere. Also like many in his field, he is concerned about the government not telling us the truth about epidemic diseases and the purposely funding of bad science. There are also conflicts of financial interest that prevent good science from prevailing.”
Second note to the TBDWG:
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov
Cc: (99 Undisclosed recipients)
Date: April 7, 2020 at 8:48 AM
Subject: Re: Microbiologist Tom Grier’s Letter to the Editor of Pharmaceutical-Technology
To the Tick-Borne Disease Working Group,
Tom Grier has asked that I add the additional comment below referencing a 2019 study that identified chronic Lyme disease in autopsy tissue from a patient who underwent extensive antibiotic treatments over the course of her 16-year-long illness.
From Tom Grier:
We are confident that if the brain-pathology research was done in earnest, that it would prove that persistence post antibiotics is real and persistent brain infections are harming millions of citizens by lowering both their productivity and their quality of life.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963883/
The Long-Term Persistence of Borrelia burgdorferi Antigens and DNA in the Tissues of a Patient with Lyme Disease
Eva Sapi,1,* Rumanah S. Kasliwala,1 Hebo Ismail,1 Jason P. Torres,1 Michael Oldakowski,1 Sarah Markland,1 Gauri Gaur,1 Anthony Melillo,1 Klaus Eisendle,2 Kenneth B. Liegner,3,4,5 Jenny Libien,6 and James E. Goldman7
Abstract
Whether Borrelia burgdorferi, the causative agent of Lyme disease, can persist for long periods in the human body has been a controversial question. The objective of this study was to see if we could find B. burgdorferi in a Lyme disease patient after a long clinical course and after long-term antibiotic treatment. Therefore, we investigated the potential presence of B. burgdorferi antigens and DNA in human autopsy tissues from a well-documented serum-, PCR-, and culture-positive Lyme disease patient, a 53-year-old female from northern Westchester County in the lower Hudson Valley Region of New York State, who had received extensive antibiotic treatments during extensive antibiotic treatments over the course of her 16-year-long illness. We also asked what form the organism might take, with special interest in the recently found antibiotic-resistant aggregate form, biofilm. We also examined the host tissues for the presence of inflammatory markers such as CD3+ T lymphocytes. Autopsy tissue sections of the brain, heart, kidney, and liver were analyzed by histological and immunohistochemical methods (IHC), confocal microscopy, fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR), and whole-genome sequencing (WGS)/metagenomics. We found significant pathological changes, including borrelial spirochetal clusters, in all of the organs using IHC combined with confocal microscopy. The aggregates contained a well-established biofilm marker, alginate, on their surfaces, suggesting they are true biofilm. We found B. burgdorferi DNA by FISH, polymerase chain reaction (PCR), and an independent verification by WGS/metagenomics, which resulted in the detection of B. burgdorferi sensu stricto specific DNA sequences. IHC analyses showed significant numbers of infiltrating CD3+ T lymphocytes present next to B. burgdorferi biofilms. In summary, we provide several lines of evidence that suggest that B. burgdorferi can persist in the human body, not only in the spirochetal but also in the antibiotic-resistant biofilm form, even after long-term antibiotic treatment. The presence of infiltrating lymphocytes in the vicinity of B. burgdorferi biofilms suggests that the organism in biofilm form might trigger chronic inflammation.
Carl Tuttle
Lyme Endemic Hudson, NH